157 related articles for article (PubMed ID: 34973857)
1. Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study.
Sasaki D; Hatakeyama S; Kawaguchi H; Hatayama Y; Ishibashi Y; Kusaka A; Noro D; Tanaka T; Ito H; Okuyama Y; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Aoki M; Ohyama C
Urol Oncol; 2022 Feb; 40(2):64.e1-64.e8. PubMed ID: 34973857
[TBL] [Abstract][Full Text] [Related]
2. Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome.
Cheng S; Arciero V; Goldberg H; Tajzler C; Manganaro A; Kozlowski N; Rowbottom L; McDonald R; Chow R; Vasisht G; Shaji S; Wong ECL; Petrovic M; Zhang L; Phillips C; Zalewski P; Kapoor A; Fleshner NE; Chow E; Emmenegger U
Cancer Manag Res; 2019; 11():9307-9319. PubMed ID: 31802949
[TBL] [Abstract][Full Text] [Related]
3. Impact of pre-treatment variables on the completion of
Lavelli V; Nappi AG; Caputo P; Asabella AN; Fanelli M; Sardaro A; Altini C; Ferrari C; Rubini G
Hell J Nucl Med; 2019; 22 Suppl 2():153-163. PubMed ID: 31802056
[TBL] [Abstract][Full Text] [Related]
4. Impact of timing of administration of bone supportive therapy on pain palliation from radium-223.
Yap KK; Wong W; Ji L; Groshen S; Quinn DI; Bryce AH; Dorff TB
Cancer Treat Res Commun; 2019; 18():100114. PubMed ID: 30529990
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer.
Sidhu A; Khan N; Phillips C; Briones J; Kapoor A; Zalewski P; Fleshner NE; Chow E; Emmenegger U
J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685670
[TBL] [Abstract][Full Text] [Related]
6. Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases.
Yamamoto Y; Okuda Y; Kanaki T; Tanaka R; Nagahara A; Nakai Y; Nakayama M; Kakimoto KI; Nishimura K
Int J Clin Oncol; 2021 Jan; 26(1):192-198. PubMed ID: 32875513
[TBL] [Abstract][Full Text] [Related]
7. Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study.
Hyväkkä A; Kääriäinen OS; Utriainen T; Löyttyniemi E; Mattila K; Reinikainen P; Sormunen J; Jääskeläinen M; Auvinen P; Minn H; Sundvall M
Cancer Med; 2023 Feb; 12(4):4064-4076. PubMed ID: 36156455
[TBL] [Abstract][Full Text] [Related]
8. Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223.
Bauckneht M; Capitanio S; Donegani MI; Zanardi E; Miceli A; Murialdo R; Raffa S; Tomasello L; Vitti M; Cavo A; Catalano F; Mencoboni M; Ceppi M; Marini C; Fornarini G; Boccardo F; Sambuceti G; Morbelli S
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861942
[No Abstract] [Full Text] [Related]
9. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223.
Al-Ezzi EM; Alqaisi HA; Iafolla MAJ; Wang L; Sridhar SS; Sacher AG; Fallah-Rad N; Jiang DM; Watson GA; Catton CN; Warde PR; Hamilton RJ; Fleshner NE; Zlotta AR; Hansen AR
Cancer Med; 2021 Sep; 10(17):5775-5782. PubMed ID: 34254464
[TBL] [Abstract][Full Text] [Related]
11. Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer.
Kim JW; Shin MS; Kang Y; Kang I; Petrylak DP
Clin Genitourin Cancer; 2018 Apr; 16(2):e469-e476. PubMed ID: 29137877
[TBL] [Abstract][Full Text] [Related]
12. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial.
Kitajima K; Igeta M; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Narita M; Daimon T; Yamakado K
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1487-1498. PubMed ID: 36539508
[TBL] [Abstract][Full Text] [Related]
13. Real-world Outcomes and Factors Predicting Survival and Completion of Radium 223 in Metastatic Castrate-resistant Prostate Cancer.
Parikh S; Murray L; Kenning L; Bottomley D; Din O; Dixit S; Ferguson C; Handforth C; Joseph L; Mokhtar D; White L; Wright G; Henry AM
Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):548-555. PubMed ID: 29934104
[TBL] [Abstract][Full Text] [Related]
14. Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients.
Caffo O; Frantellizzi V; Monari F; Sbrana A; Costa RP; Pinto C; Tucci M; Baldari S; Facchini G; Bortolus R; Alongi F; Alongi P; Palermo A; Fanti S; Biasco E; Murabito A; Filice A; Zichi C; Pignata S; Borsatti E; Salgarello M; Spada M; Cortesi E; Vincentis G
Future Oncol; 2021 Mar; 17(7):807-815. PubMed ID: 33508980
[No Abstract] [Full Text] [Related]
15. Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).
George DJ; Agarwal N; Sartor O; Sternberg CN; Tombal B; Saad F; Miller K; Constantinovici N; Guo H; Reeves J; Jiao X; Sandström P; Verholen F; Higano CS; Shore N
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):306-313. PubMed ID: 35190653
[TBL] [Abstract][Full Text] [Related]
16. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.
Morris MJ; Loriot Y; Sweeney CJ; Fizazi K; Ryan CJ; Shevrin DH; Antonarakis ES; Pandit-Taskar N; Deandreis D; Jacene HA; Vesselle H; Petrenciuc O; Lu C; Carrasquillo JA; Higano CS
Eur J Cancer; 2019 Jun; 114():107-116. PubMed ID: 31082669
[TBL] [Abstract][Full Text] [Related]
17. Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer.
Wong WW; Anderson EM; Mohammadi H; Daniels TB; Schild SE; Keole SR; Choo CR; Tzou KS; Bryce AH; Ho TH; Quevedo FJ; Vora SA
Clin Genitourin Cancer; 2017 Dec; 15(6):e969-e975. PubMed ID: 28545997
[TBL] [Abstract][Full Text] [Related]
18. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
[TBL] [Abstract][Full Text] [Related]
19. Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer.
Hashimoto K; Miyoshi Y; Shindo T; Hori M; Tsuboi Y; Kobayashi K; Fukuta F; Tanaka T; Miyamoto S; Maehana T; Okada M; Nishiyama N; Yanase M; Kato R; Hotta H; Kunishima Y; Takahashi A; Hinotsu S; Sakata KI; Kitamura H; Uemura H; Masumori N
Cancer Med; 2020 Nov; 9(22):8579-8588. PubMed ID: 32964674
[TBL] [Abstract][Full Text] [Related]
20. A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer.
Miyoshi Y; Tsutsumi S; Yasui M; Kawahara T; Uemura KI; Hayashi N; Nozawa M; Yoshimura K; Uemura H; Uemura H
World J Urol; 2021 Sep; 39(9):3323-3328. PubMed ID: 33644830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
